Oncternal sells assets for up to $68m and calls it quits
American oncology company Oncternal Therapeutics is to wind down operations after announcing the sale of its main drug programmes. Delaware-based…
News
Sanofi’s riliprubart gains ODD status from Japan’s MHLW for CIDP
AbbVie buys $2.1bn Capstan, adding new in vivo CAR-T to pipeline
Piramal Pharma announces $90m investment to expand US sites
FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency
WHO accuses China of withholding Covid-19 genetic data
Vetter breaks ground on $285m US clinical manufacturing site
FDA removes safety programme for CAR-T therapies to boost uptake
